High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history

Journal of Clinical Oncology

Volumn 25, Issue 24, 2007, Pages 3644-3648

  O'Neil, Bert H ^a   Allen, Robert ^a   Spigel, David R ^a   Stinchcombe, Thomas E ^a   Moore, Dominic T ^a   Berlin, Jordan D ^a   Goldberg, Richard M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DEXAMETHASONE;

ADULT; AGED; ARTICLE; BREAST CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DATA ANALYSIS; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MEDICAL RECORD; PANCREAS CANCER; PRIORITY JOURNAL; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANAPHYLAXIS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NORTH CAROLINA; RECEPTOR, EPIDERMAL GROWTH FACTOR; TENNESSEE;

EID: 34548487155     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.7812     Document Type: Article

References (18)

1. Patel DD, Goldberg RM: Cetuximab-associated infusion reactions: Pathology and management. Oncology (Williston Park) 20:1373-1382, 2006; discussion 1382, 1392-1394:1397, 2006
2. Mendelsohn J, Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 33:369-385, 2006
3. Perez-Soler R, Saltz L: Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol 23:5235-5246, 2005
4. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
5. Saltz LB, Lenz HJ, Hochster H, et al: Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol 23:248s, 2005 (abstr 3508)
6. Abubakr Y, Eng C, Wong L, et al: Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC). J Clin Oncol 24:160s, 2006 (abstr 3556)
7. Melamed J, Stahlman JE: Rapid desensitization and rush immunotherapy to trastuzumab (Herceptin). J Allergy Clin Immunol 110:813-814, 2002
8. Shepherd GM: Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 24:253-262, 2003
9. Meyer L, Zuberbier T, Worm M, et al: Hypersensitivity reactions to oxaliplatin: Cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 20:1146-1147, 2002
10. Saltz L, Easley C, Kirkpatrick P: Panitumumab. Nat Rev Drug Discov 5:987-988, 2006
11. Amgen: Amgen discontinues Vectibix treatment in PACCE trial evaluating Vectibix as part of triple combination regimen. March 22, 2007. http://www.amgen.com/media/media_pr_detail.jsp7releaseID=977186
12. Venook A, Niedzwiecki D, Hollis D, et al: Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/ 5FU/LV (FOLFOX) +/- cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol 24:148s, 2006 (abstr 3509)
13. Gibson TB, Ranganathan A, Grothey A: Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6:29-31, 2006
14. Reference deleted by author.
15. Reference deleted by author.
16. Reference deleted by author.
17. Burtness B, Goldwasser MA, Flood W, et al: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 23: 8646-8654, 2005
18. Sampson HA, Munoz-Furlong A, Bock SA, et al: Symposium on the definition and management of anaphylaxis: Summary report. J Allergy Clin Immunol 115:584-591, 2005